Chhattisgarh Rejects Approved Bharat Biotech Vaccine Without Efficacy Data | India News
India, which has reported the world’s second-highest number of Covid-19 cases after the United States, has vaccinated more than 7 million front-line workers since January 16 using Covaxin developed by Bharat Biotech, as well as a vaccine licensed by AstraZeneca and University of Oxford.
So far, the federal government has ordered 10 million doses of Covaxin and 21 million injections of AstraZeneca, manufactured locally by the Serum Institute of India for low- and middle-income countries.
Bharat Biotech, which created Covaxin with the state Indian Council of Medical Research, has said that efficacy data from the late-stage clinical trial on nearly 26,000 volunteers will be available next month, drawing criticism from epidemiologists that too much was approved. hurriedly. for emergency use.
Developers and India’s drug regulator, however, say the vaccine is safe and effective based on early and intermediate studies.
Chhattisgarh, a central-eastern state of about 32 million people, said he was likely to be sent injections of Covaxin soon after starting his campaign with 588,000 doses of the AstraZeneca product.
“There is an inhibition / concern among the wider community regarding the use of Covaxin,” wrote State Health Minister TS Singh Deo in a letter to his federal counterpart Harsh Vardhan and shared it on Twitter.
“This concern stems from the fact that phase 3 clinical trials have not yet been completed.”
▪️The absence of an expiration date on the vaccine vials. I have asked you to stop the supply of COVAXIN t… https://t.co/6bSy9lyf88
– TS Singh Deo (@TS_SinghDeo) 1613032846000
Singh Deo also said on Twitter that the Covaxin vials do not show any expiration dates and that he had requested that Vardhan stop supplying Chhattisgarh “until these issues are addressed to the satisfaction of our Health Department to avoid wasted doses. of anticipated expiration of the drug “.
A spokeswoman for the federal Ministry of Health and Family Welfare did not respond to a request for comment.
Bharat Biotech said it could comment later. It plans to soon export the injection to Brazil and the United Arab Emirates.